Comparison of glycopyrronium versus tiotropium on the time to clinically important deteriorations in patients with COPD: a post-hoc analysis of randomized trials

Glycopyrronium is a once-daily, inhaled long-acting muscarinic antagonist (LAMA) demonstrating similar efficacy to inhaled tiotropium in patients with moderate-to-severe COPD; however, the benefit of LAMAs on COPD symptoms has been variable. COPD is a progressive disease in which many patients devel...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Urzo, Anthony, Bader, Giovanni, Shen, Steven, Goyal, Pankaj, Altman, Pablo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5967309/
https://www.ncbi.nlm.nih.gov/pubmed/29795478
http://dx.doi.org/10.1038/s41533-018-0084-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5967309/
https://www.ncbi.nlm.nih.gov/pubmed/29795478
http://dx.doi.org/10.1038/s41533-018-0084-8

Ejemplares similares